<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04667416</url>
  </required_header>
  <id_info>
    <org_study_id>PGF-201</org_study_id>
    <nct_id>NCT04667416</nct_id>
  </id_info>
  <brief_title>Safety and Preliminary Efficacy of PalinGen Flow Amniotic Tissue Allograft in Chronic Ulcers of the Lower Extremities</brief_title>
  <official_title>A Prospective, Multicenter, Randomized, Controlled Clinical Investigation of PalinGen® Flow Amniotic Tissue Allograft to Assess Safety, Tolerability, and Preliminary Efficacy for the Treatment of Chronic Lower Extremity Cutaneous Ulcers Compared to Standard of Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amnio Technology, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amnio Technology, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and preliminary efficacy of PalinGen® Flow&#xD;
      for the treatment of chronic ulcers of the lower legs and feet.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 19, 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants in the PalinGen Flow plus SOC group versus SOC alone with treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>All adverse events (AEs) and serious adverse events (SAEs) will be recorded from the time of signing of the informed consent form through Week 64.</time_frame>
    <description>Treatment-emergent adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and graded per the CTCAE Version 5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants in the PalinGen Flow plus SOC group versus SOC alone who achieve complete ulcer closure by Week 12.</measure>
    <time_frame>BWAT assessment and wound imaging will be performed at each study visit through end of treatment (Week 12)</time_frame>
    <description>Complete wound closure will be assessed by the Bates-Jensen Wound Assessment Tool (BWAT) and a photographic imaging and measurement device.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Chronic Ulcer of Lower Extremity</condition>
  <arm_group>
    <arm_group_label>Standard of Care (SOC)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will receive SOC for chronic ulcers of the lower extremities.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PalinGen Flow Treatment plus SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive wound size-dependent dose of PalinGen Flow liquid human amniotic tissue allograft by subcutaneous injection in addition to SOC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PalinGen Flow Amniotic Tissue Allograft</intervention_name>
    <description>Participants will receive wound size-dependent dose of PalinGen Flow liquid human amniotic tissue allograft by subcutaneous injection in addition to SOC.</description>
    <arm_group_label>PalinGen Flow Treatment plus SOC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to read, understand and sign the informed consent form (ICF)&#xD;
&#xD;
          -  Available and willing to complete all study assessments&#xD;
&#xD;
          -  At least 12 weeks post lower extremity revascularization procedure, if one has been&#xD;
             performed&#xD;
&#xD;
          -  Have chronic ulcer(s) of the lower extremities with the following characteristics:&#xD;
&#xD;
               -  Of diabetic or vascular etiology&#xD;
&#xD;
               -  Duration of ≥4 weeks, unresponsive to SOC&#xD;
&#xD;
               -  ≤20 cm2 in area&#xD;
&#xD;
               -  Extend through the full thickness of the skin but not down to muscle, tendon, or&#xD;
                  bone&#xD;
&#xD;
          -  For subjects with VLU:&#xD;
&#xD;
               -  Ulcer area is ≥1.5 cm2 and ≤20 cm2 and with a clean, granulating base with&#xD;
                  minimal adherent slough&#xD;
&#xD;
               -  Ulcer location is at or above the ankle (malleolus) and below the knee&#xD;
&#xD;
               -  Ulcer location is appropriate for use of compression therapy treatment&#xD;
&#xD;
          -  For subjects with DFU:&#xD;
&#xD;
               -  Ulcer area is ≥1.5 cm2 and ≤ 20 cm2 and is amenable to off-loading&#xD;
&#xD;
               -  Subject has diabetes mellitus (Type 1 or Type 2), requiring insulin or&#xD;
                  oral/injectable medications to control blood glucose levels&#xD;
&#xD;
               -  Glycosylated hemoglobin (HbA1c) level at screening is &lt;12%&#xD;
&#xD;
          -  Adequate circulation to the affected lower extremities&#xD;
&#xD;
          -  Total serum bilirubin, alanine aminotransferase (ALT) and/or aspartate&#xD;
             aminotransferase (AST), hemoglobin, WBC, and PLT count all within limits specified in&#xD;
             study protocol&#xD;
&#xD;
          -  No renal impairment or mild renal impairment, defined as creatinine clearance ≥50&#xD;
             mL/min (by Cockroft-Gault estimation)&#xD;
&#xD;
          -  Male subjects and female subjects of childbearing potential must use acceptable&#xD;
             methods of contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical evidence of ongoing infection and/or receipt of IV, oral, or topical&#xD;
             antimicrobials at the Baseline Visit&#xD;
&#xD;
          -  Wheelchair bound or bed-ridden (ambulatory with assistance is acceptable)&#xD;
&#xD;
          -  Ulceration at the site of amputation&#xD;
&#xD;
          -  Undergoing renal dialysis&#xD;
&#xD;
          -  Known or suspected malignancy in the target ulcer, or a history of cancer in the&#xD;
             preceding 5 years (other than carcinoma in situ of the cervix or adequately treated&#xD;
             non-melanoma skin cancer)&#xD;
&#xD;
          -  Documented history of osteomyelitis at the target ulcer location within 6 months of&#xD;
             screening&#xD;
&#xD;
          -  Current treatment or anticipated need for treatment over the course of the study with:&#xD;
&#xD;
               -  Immunosuppressants (including topical or systemic corticosteroids or&#xD;
                  glucocorticoids)&#xD;
&#xD;
               -  Cytotoxic chemotherapy&#xD;
&#xD;
               -  Growth hormone&#xD;
&#xD;
               -  Oral or systemic antifungal or antituberculosis treatment&#xD;
&#xD;
          -  History of radiation at the ulcer site&#xD;
&#xD;
          -  New York Heart Association Class III or IV congestive heart failure or uncontrolled&#xD;
             cardiac dysrhythmia&#xD;
&#xD;
          -  Diagnosis of autoimmune disease(s) (rheumatoid arthritis, lupus, psoriasis, Sjogren's&#xD;
             syndrome) or arthritis requiring corticosteroid treatment&#xD;
&#xD;
          -  Target ulcer(s) previously treated with negative pressure, hyperbaric oxygen, or&#xD;
             tissue engineered materials (eg, Apligraf®, EpiFix® or Dermagraft®) or other scaffold&#xD;
             materials (eg, Oasis, Matristem) within 4 weeks prior to Screening Visit&#xD;
&#xD;
          -  Target ulcer(s) anticipated to require negative pressure wound therapy or hyperbaric&#xD;
             oxygen at any time during the study&#xD;
&#xD;
          -  Subjects with VLU who have:&#xD;
&#xD;
               -  Deep vein thrombosis diagnosed within 4 weeks prior to Screening Visit&#xD;
&#xD;
               -  Refusal or inability to tolerate compression therapy&#xD;
&#xD;
          -  Subjects with DFU who have:&#xD;
&#xD;
               -  Active Charcot foot (stable chronic Charcot foot is not exclusionary)&#xD;
&#xD;
               -  Ulcers on toes 2, 3, 4, and/or 5 only (ulcer on plantar surface of the great toe&#xD;
                  only is not exclusionary)&#xD;
&#xD;
          -  Pregnant or breast feeding&#xD;
&#xD;
          -  Allergic to DMSO&#xD;
&#xD;
          -  Healing of target ulcer is observed to be ≥35% at the end of the Run-in Period&#xD;
             (between Screening and Baseline Visits)&#xD;
&#xD;
          -  Presence of any condition(s) which compromises the subject's ability to complete this&#xD;
             study, including subjects with a known history of poor adherence to medical treatment&#xD;
&#xD;
          -  Subjects who, in the opinion of the Investigator, are not able to comply with study&#xD;
             requirements&#xD;
&#xD;
          -  Treatment with an investigational drug(s) or device(s) within the 4 weeks preceding&#xD;
             Screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sponsor Regulatory Affairs Manager</last_name>
    <phone>888-232-8550</phone>
    <email>quality@amniotechnology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Center for Clinical Research</name>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <zip>95608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irena Andreychenko</last_name>
      <phone>800-363-1069</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Research</name>
      <address>
        <city>Castro Valley</city>
        <state>California</state>
        <zip>94546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irena Andreychenko</last_name>
      <phone>916-459-4398</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Limb Preservation Platform</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noe Guerrero</last_name>
      <phone>800-714-8011</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Peralta</last_name>
      <phone>800-363-1069</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ILD Research Center</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Martinez</last_name>
      <phone>760-350-5080</phone>
      <phone_ext>6</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acclaim Bone &amp; Joint Institute and Plastic Surgery</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>April Bell</last_name>
      <phone>817-702-5362</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Futuro Clinical Trials</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Rodriguez</last_name>
      <phone>956-999-8399</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 8, 2020</study_first_submitted>
  <study_first_submitted_qc>December 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2020</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic ulcer</keyword>
  <keyword>Venous stasis ulcer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

